Halozyme Therapeutics Inc (HALO)

47.54 +0.38 (+0.81%) USD  |  NASDAQ  |  Dec 24, 16:00
More

Halozyme Therapeutics Research and Development Expense (Quarterly): 18.46M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Lexicon Pharmaceuticals Inc 25.78M
Novavax Inc 87.16M
Kura Oncology Inc 41.70M
TransMedics Group Inc 14.27M
Pulmonx Corp 3.744M